PD-L1 expression detected by immunohistochemistry (IHC), and tumor mutational burden (TMB) measured by next generation sequencing (NGS) are the best-studied biomarkers for the response to immunotherapy in NSCLC [6]. Here, CD274 is linked to non-small cell lung carcinoma.